• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 3. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 4. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 5. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrazines

Introduction to 1-(pyrazin-2-yl)cyclobutane-1-carboxylic acid (CAS No. 1480954-26-4)

1-(pyrazin-2-yl)cyclobutane-1-carboxylic acid (CAS No. 1480954-26-4) is a specialized organic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry due to its unique structural properties and potential biological activities. This compound, featuring a cyclobutane ring fused with a pyrazine moiety, presents an intriguing scaffold for the development of novel therapeutic agents. The combination of these structural elements not only enhances its chemical diversity but also opens up possibilities for diverse interactions with biological targets, making it a promising candidate for further exploration in drug discovery.

The pyrazine moiety, a six-membered heterocyclic ring containing two nitrogen atoms, is well-known for its presence in numerous bioactive molecules. Its ability to engage in hydrogen bonding and π-stacking interactions makes it a valuable component in designing molecules with specific binding affinities. In contrast, the cyclobutane ring introduces rigidity and spatial constraints, which can be strategically exploited to optimize pharmacokinetic profiles and target specificity. This unique combination in 1-(pyrazin-2-yl)cyclobutane-1-carboxylic acid suggests that it may exhibit properties distinct from those of either moiety alone.

Recent advancements in computational chemistry and molecular modeling have enabled researchers to predict the potential biological activities of such compounds with greater accuracy. The structural features of 1-(pyrazin-2-yl)cyclobutane-1-carboxylic acid have been computationally analyzed to identify possible interactions with various biological targets, including enzymes and receptors relevant to human health. These studies have highlighted the compound's potential as a scaffold for developing inhibitors or modulators of key metabolic pathways.

In particular, the pyrazine ring has been shown to interact with nucleophilic centers in biological molecules, which could be exploited for the development of enzyme inhibitors. The cyclobutane ring, on the other hand, can provide steric hindrance that may enhance binding affinity by optimizing the distance between key functional groups and the target site. This synergistic effect has been observed in other related compounds where both moieties are present, suggesting that 1-(pyrazin-2-yl)cyclobutane-1-carboxylic acid may exhibit similar advantages.

One of the most exciting aspects of this compound is its potential application in the development of treatments for neurological disorders. Pyrazine derivatives have been extensively studied for their role in modulating neurotransmitter systems, particularly those involving glutamate and GABA receptors. The structural motif of 1-(pyrazin-2-yl)cyclobutane-1-carboxylic acid could allow it to interact with these receptors or related signaling pathways, offering a new approach to treating conditions such as epilepsy, Parkinson's disease, and Alzheimer's disease.

Furthermore, the compound's unique structure may also make it useful in addressing inflammatory diseases. Inflammatory processes often involve complex signaling pathways that can be modulated by small molecules. The ability of 1-(pyrazin-2-yl)cyclobutane-1-carboxylic acid to engage with multiple targets simultaneously could provide a more comprehensive therapeutic approach compared to traditional single-target drugs.

Another area where this compound shows promise is in anticancer research. Cancer cells often exhibit altered metabolic pathways that can be exploited for therapeutic gain. The structural features of 1-(pyrazin-2-yl)cyclobutane-1-carboxylic acid could allow it to interfere with key enzymes involved in cancer cell metabolism, such as those involved in glycolysis or fatty acid synthesis. Additionally, its ability to induce apoptosis or inhibit cell proliferation has been suggested based on preliminary computational studies.

The synthesis of 1-(pyrazin-2-yl)cyclobutane-1-carboxylic acid presents an interesting challenge due to the need to integrate two distinct structural motifs into a single molecule. However, recent advances in synthetic methodologies have made it increasingly feasible to construct complex organic molecules like this one efficiently and with high precision. Techniques such as transition metal-catalyzed cross-coupling reactions have been particularly useful in forming the necessary carbon-nitrogen bonds between the pyrazine and cyclobutane moieties.

Once synthesized, the compound can be subjected to rigorous biological testing to evaluate its efficacy and safety profiles. High-throughput screening (HTS) technologies allow researchers to rapidly test thousands of compounds against various biological targets, providing valuable data on their potential therapeutic applications. Additionally, structure-activity relationship (SAR) studies can be conducted to modify specific parts of the molecule and optimize its biological activity further.

The growing interest in 1-(pyrazin-2-yl)cyclobutane-1-carboxylic acid underscores the importance of exploring novel molecular scaffolds in drug discovery. Its unique combination of structural features offers a rich foundation for designing molecules with tailored properties for specific therapeutic applications. As research continues to uncover new biological functions and synthetic strategies, compounds like this one are likely to play an increasingly significant role in the development of next-generation pharmaceuticals.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)